Literature DB >> 14967170

Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?

Ingrid Zitnanová1, Peter Korytár, Okezie I Aruoma, Mária Sustrová, Iveta Garaiová, Jana Muchová, Terézia Kalnovicová, Siegfried Pueschel, Zdenka Duracková.   

Abstract

BACKGROUND: Down syndrome (DS) is a chromosomal abnormality (trisomy 21) leading to mental retardation, to the characteristic change of individual's phenotype and to the pathological features of Alzheimer disease. Patients with DS have elevated ratio of superoxide dismutase to (catalase plus glutathione peroxidase) with respect to controls in all age categories suggesting that oxidative imbalance contributes to the clinical manifestation of accelerated aging.
RESULTS: We report that persons with DS have elevated uric acid levels compared with controls, 348.56+/-22.78 versus 284.00+/-20.86 micromol/l (p=0.018). The levels of hypoxanthine and xanthine in DS children (6.35+/-0.31 and 1.02+/-0.23 micromol/l) were significantly lower than in controls (7.83+/-0.59 and 2.43+/-0.66 micromol/l). This result suggests increased conversion of hypoxanthine and xanthine to uric acid with subsequent free radical-dependent oxidation of uric acid to allantoin, mechanisms potentiated by the oxidative stress in DS. Allantoin is a nonenzymatic oxidative product of uric acid in human. In DS individuals, the levels of allantoin were significantly higher than those in healthy controls (18.58+/-2.27 and 14.07+/-1.07 micromol/l, respectively, p=0.03).
CONCLUSIONS: Our data supported the presumption of increased oxidative stress in DS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967170     DOI: 10.1016/j.cccn.2003.11.020

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  22 in total

Review 1.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

2.  The relationship between uric acid and its oxidative product allantoin: a potential indicator for the evaluation of oxidative stress in birds.

Authors:  Ella Tsahar; Zeev Arad; Ido Izhaki; Christopher G Guglielmo
Journal:  J Comp Physiol B       Date:  2006-05-17       Impact factor: 2.200

3.  Biochemical measurement of neonatal hypoxia.

Authors:  Megan S Plank; Teleka C Calderon; Yayesh Asmerom; Danilo S Boskovic; Danilyn M Angeles
Journal:  J Vis Exp       Date:  2011-08-24       Impact factor: 1.355

4.  α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial.

Authors:  S Mustafa Nachvak; T Reza Neyestani; S Ali Mahboob; S Sabour; S Ali Keshawarz; J R Speakman
Journal:  Eur J Clin Nutr       Date:  2014-06-18       Impact factor: 4.016

5.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

6.  Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry.

Authors:  Kyung Mee Kim; George N Henderson; Reginald F Frye; Cheryl D Galloway; Nancy J Brown; Mark S Segal; Witcha Imaram; Alexander Angerhofer; Richard J Johnson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-25       Impact factor: 3.205

7.  Clinical course and outcome for critically ill children with Down syndrome: a retrospective cohort study.

Authors:  Shane M Tibby; Andrew Durward; Chong Tien Goh; Kentigern Thorburn; Kevin Morris; Mike Broadhead; Mark J Peters
Journal:  Intensive Care Med       Date:  2012-05-15       Impact factor: 17.440

Review 8.  Molecular genetic analysis of Down syndrome.

Authors:  David Patterson
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

9.  Prevalence of Endocrine Disorders Among 6078 Individuals With Down Syndrome in the United States.

Authors:  Anne Rivelli; Veronica Fitzpatrick; Danielle Wales; Laura Chicoine; Gengjie Jia; Andrey Rzhetsky; Brian Chicoine
Journal:  J Patient Cent Res Rev       Date:  2022-01-17

10.  Redox processes in neurodegenerative disease involving reactive oxygen species.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.